Startups
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 10, 2025 | Renasant Bio Raises $54.5M in Seed Funding | Renasant Bio, a Berkeley, CA-based developer of disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), raised $54.5M in Seed funding. The round was led by 5AM Ventures, alongside other life sciences investors... |
| Renasant Bio | “Home | RenasantBio” |
Reviews 0
FAQ about Renasant Bio
What has the press written about Renasant Bio?
Parsers VC has collected 3 articles mentioning Renasant Bio, among them “Renasant Bio Raises $54.5M in Seed Funding” (Jul 10, 2025) and “Renasant Bio”.
Is Renasant Bio still active?
Yes, Renasant Bio is active; its latest activity on Parsers VC dates from Jul 10, 2026.